S. Klassen, J. Senefeld, Patrick W. Johnson, R. Carter, C. Wiggins, S. Shoham, B. Grossman, J. Henderson, J. Musser, E. Salazar, W. Hartman, N. Bouvier, Sean T. H. Liu, L. Pirofski, S. Baker, N. van Helmond, R. Wright, D. Fairweather, K. A. Bruno, Zhen Wang, N. Paneth, A. Casadevall, M. Joyner
medRxiv, 2020
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials, matched control, and case-series studies. Fixed-effects analyses demontrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a a57% reduction in mortality rate (13%) compared to matched-patients receiving standard treatments (25%; OR: 0.43, P < 0.001). These data provide evidence favouring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.
Cited by 64 publications.
Field of study: Medicine